feedback

Course Director

Daniel Petrylak, MD
Daniel Petrylak, MD

Professor of Medicine and of Urology
Yale University
New Haven, Connecticut, USA

Accredited by

USF Health

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2019-Mar-28
Expiration Date:2020-Mar-27
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of Charge

Support

This activity is supported by an independent educational grant from Astellas and Seattle Genetics, Inc.

Activity Description and Educational Objectives

In this activity, an expert in urothelial cancer discusses the emerging treatment landscape for patients with advanced urothelial carcinoma.

Upon completion of this activity, participants should be better able to:
  • Determine when patients with urothelial cancer are progressing on immunotherapies
  • Evaluate available therapeutic options and antibody-drug conjugate (ADC) therapies in development for the management of patients with urothelial cancer progressing on immunotherapies
  • Apply expert-guided and evidence-based strategies to improve outcomes for patients with urothelial cancer who have progressed on immunotherapies

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologic oncologists, and other clinicians involved in treatment of urothelial cancer.

Faculty Disclosure Statement / Conflict of Interest Policy

USF Health has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. USF Health’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director

Daniel Petrylak, MD
Professor of Medicine and of Urology
Yale University
New Haven, Connecticut, USA

Daniel Petrylak, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Amgen Inc.; Astellas Pharma EMEA; AstraZeneca Plc; Bayer AG; Bellicum Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Clovis Oncology, Inc.; Dendron Pharmaceuticals LLC.; Eli Lilly and Company; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Ferring Holding SA; Johnson & Johnson Services, Inc.; Medivation Inc.; Millennium Pharmaceuticals, Inc.; Pfizer Inc.; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.

Grant/Research Support from Agensys, Inc.; Astellas Pharma EMEA; AstraZeneca Plc; Bayer AG; Bristol-Myers Squibb Company; Clovis Oncology, Inc.; Dendron Pharmaceuticals LLC.; Endocyte; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Innocrin Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; MedImmune, LLC; Medivation Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Progenics Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; and Sotio, LLC.

Major Stock Shareholder in Bellicum Pharmaceuticals, Inc. and Tyme Technologies, Inc.

Peer Reviewer

Trushar Patel, MD
Morsani College of Medicine University of South Florida
Tampa, Florida, USA

Trushar Patel, MD has no financial interests/relationships or affiliations in relation to this activity.

Answers in CME Medical Director

Serena Welch has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Answers in CME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

USF Health
This CME activity is jointly provided by USF Health and Answers in CME.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.

Media: Enduring Material
Release and Expiration Dates: March 28, 2019 - March 27, 2020
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.

© 2018-2019, Answers in CME

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.